Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients.

Hui CY, Rudra S, Ma S, Campian JL, Huang J.

J Neurooncol. 2019 May;143(1):129-136. doi: 10.1007/s11060-019-03146-7. Epub 2019 Mar 12.


Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.

Rudra S, Hui C, Rao YJ, Samson P, Lin AJ, Chang X, Tsien C, Fergus S, Mullen D, Yang D, Thotala D, Hallahan D, Campian JL, Huang J.

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):217-225. doi: 10.1016/j.ijrobp.2018.01.069. Epub 2018 Feb 1.


Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.

Shields LB, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S, Bourne TD, LaRocca R, Spalding AC.

Radiat Oncol. 2015 Oct 31;10:222. doi: 10.1186/s13014-015-0527-0.


Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era.

Byun HK, Kim N, Yoon HI, Kang SG, Kim SH, Cho J, Baek JG, Chang JH, Suh CO.

Radiat Oncol. 2019 Mar 27;14(1):51. doi: 10.1186/s13014-019-1256-6.


Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme.

Kole AJ, Park HS, Yeboa DN, Rutter CE, Corso CD, Aneja S, Lester-Coll NH, Mancini BR, Knisely JP, Yu JB.

Cancer. 2016 Aug 1;122(15):2364-70. doi: 10.1002/cncr.30063. Epub 2016 May 12.


Subventricular Zone Radiation Dose and Outcome for Glioblastoma Treated Between 2006 and 2012.

Murchison SC, Wiksyk B, Gossman S, Jensen B, Sayers D, Lesperance M, Truong PT, Alexander A.

Cureus. 2018 Nov 21;10(11):e3618. doi: 10.7759/cureus.3618.


Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.

Sun MZ, Oh T, Ivan ME, Clark AJ, Safaee M, Sayegh ET, Kaur G, Parsa AT, Bloch O.

J Neurosurg. 2015 May;122(5):1144-50. doi: 10.3171/2014.9.JNS14193. Epub 2015 Mar 13.


Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.

J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.


Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival.

Mason M, Maurice C, McNamara MG, Tieu MT, Lwin Z, Millar BA, Menard C, Laperriere N, Milosevic M, Atenafu EG, Mason W, Chung C.

J Neurooncol. 2017 May;132(3):463-471. doi: 10.1007/s11060-017-2395-y. Epub 2017 Mar 22.


Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme.

Zincircioglu SB, Kaplan MA, Isikdogan A, Cil T, Karadayi B, Dirier A, Kucukoner M, Inal A, Yildiz I, Aggil F, Donmez O, Urakci Z, Pekkolay Z, Firat U.

J BUON. 2012 Jan-Mar;17(1):124-7.


Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma.

Haque W, Verma V, Butler EB, Teh BS.

J Neurooncol. 2017 Oct;135(1):173-181. doi: 10.1007/s11060-017-2563-0. Epub 2017 Jul 7.


Patterns of Care and Outcomes of Hypofractionated Chemoradiation Versus Conventionally Fractionated Chemoradiation for Glioblastoma in the Elderly Population.

Haque W, Verma V, Butler EB, Teh BS.

Am J Clin Oncol. 2018 Feb;41(2):167-172. doi: 10.1097/COC.0000000000000417.


Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.

Molitoris JK, Rao YJ, Patel RA, Kane LT, Badiyan SN, Gittleman H, Barnholtz-Sloan JS, Bentzen SM, Kruser TJ, Huang J, Mehta MP.

J Neurooncol. 2017 Sep;134(2):331-338. doi: 10.1007/s11060-017-2529-2. Epub 2017 Jun 22.


Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.

Huang J, DeWees TA, Badiyan SN, Speirs CK, Mullen DF, Fergus S, Tran DD, Linette G, Campian JL, Chicoine MR, Kim AH, Dunn G, Simpson JR, Robinson CG.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1000-1007. doi: 10.1016/j.ijrobp.2015.04.005. Epub 2015 Apr 8.


Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.

Paik W, Kim HS, Choi CG, Kim SJ.

Korean J Radiol. 2016 Jan-Feb;17(1):117-26. doi: 10.3348/kjr.2016.17.1.117. Epub 2016 Jan 6.


The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.

Millward CP, Brodbelt AR, Haylock B, Zakaria R, Baborie A, Crooks D, Husband D, Shenoy A, Wong H, Jenkinson MD.

Acta Neurochir (Wien). 2016 Oct;158(10):1943-53. doi: 10.1007/s00701-016-2928-8. Epub 2016 Aug 15.


Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.

Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez DR, Welsh J, Cox JD, Crane CH, Hsu CC, Lin SH.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):128-135. doi: 10.1016/j.ijrobp.2017.05.037. Epub 2017 Jun 1.


Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.


Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.

Mendez JS, Govindan A, Leong J, Gao F, Huang J, Campian JL.

J Neurooncol. 2016 Apr;127(2):329-35. doi: 10.1007/s11060-015-2037-1. Epub 2016 Jan 4.


Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.

Jan CI, Tsai WC, Harn HJ, Shyu WC, Liu MC, Lu HM, Chiu SC, Cho DY.

Front Immunol. 2018 May 29;9:727. doi: 10.3389/fimmu.2018.00727. eCollection 2018.

Supplemental Content

Support Center